Shanghai GoBroad Cancer Hospital
A leading tertiary cancer research hospital in Shanghai and the solid tumour specialty centre of GoBroad Healthcare Group, affiliated with China Pharmaceutical University. The hospital operates 406 beds in Phase I with approximately 700 additional beds under development in Phase II, organised around five disease-focused programmes β gastrointestinal cancers, lung cancers, hepatobiliary-pancreatic cancers, bone and soft tissue sarcomas, and breast cancers β supported by Phase I clinical trial wards, a central laboratory, TomoTherapy linear accelerator and an active multidisciplinary care (MDC) model.
About Shanghai GoBroad Cancer Hospital
Shanghai GoBroad Cancer Hospital (δΈζ΅·ι«εθΏη€ε»ι’) is a leading tertiary cancer research hospital located in Shanghai, China. It operates as the solid tumour specialty hospital within GoBroad Healthcare Group's seven-hospital research network across Beijing, Shanghai and Guangzhou, and is affiliated with China Pharmaceutical University. The hospital's Phase I operations include 406 beds and active Phase I clinical trial wards, with approximately 700 additional beds under development in Phase II. Clinical infrastructure includes PET-CT, 64-slice multi-layer CT, MRI, and TomoTherapy linear accelerator for advanced image-guided radiotherapy, supporting the hospital's positioning as a comprehensive solid tumour diagnostic, treatment and clinical research facility.
The hospital is organised around five disease-focused programmes: gastrointestinal cancers (esophageal, gastric, colorectal); lung cancers; hepatobiliary-pancreatic cancers (liver, biliary tract, pancreatic); bone and soft tissue sarcomas; and breast cancers. Patient care is delivered through an International Multidisciplinary Care (MDC) model, considered the current best practice for complex cancer management β bringing together surgical oncologists, medical oncologists, radiation oncologists, radiologists, pathologists and supportive care teams for each complex case. The hospital offers dedicated International Consultation pathways (η³θ―·ε½ι δΌθ―) for patients travelling from outside China, alongside domestic multidisciplinary consultation services. Clinical research is a core pillar: the hospital is a registered drug clinical trial institution with active Phase I-IV protocols, recently dispensing the first in-hospital prescription of encorafenib for BRAF-mutant colorectal cancer in Shanghai, marking a new advance for this difficult-to-treat colorectal cancer subtype.
Clinical leadership is anchored by Honorary President Professor Qin Shukui (秦ει΅), Chief Consultant for Hepatobiliary-Pancreatic Tumours, Chief Physician, Professor and PhD supervisor β one of China's most internationally recognised medical oncologists, with particular expertise in liver cancer (hepatocellular carcinoma), biliary tract cancer and pancreatic cancer. Professor Qin recently presented Asian patient data from the TOURMALINE study at the 9th CSCO (Chinese Society of Clinical Oncology) Jinling Tumour Annual Conference, supporting flexible first-line immune combination chemotherapy in advanced biliary tract cancer, and is widely cited for his leadership in immunotherapy advances for liver cancer. Additional faculty include Professor Li Jin (medical oncology and gastrointestinal cancer clinical trials), Professor Lu Ming (hepatobiliary and gastrointestinal oncology, also active in nuclear medicine) and other senior specialists. The hospital has hosted health consul-led visits from the US Consulate-General focused on innovative drug clinical cooperation, reflecting its active international academic engagement.
CancerFax works with international and Indian families considering Shanghai GoBroad Cancer Hospital primarily for solid tumour cases where multidisciplinary care, access to active Phase I-IV clinical trials, or consultation with Professor Qin Shukui or other senior specialists may genuinely change the treatment plan. We help patients understand whether Shanghai GoBroad is the right clinical fit for their specific diagnosis, alongside parallel review at alternative Chinese cancer centres including Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing (China's national cancer flagship), Sun Yat-sen University Cancer Center in Guangzhou (national solid tumour flagship for the South), Fudan University Shanghai Cancer Center, and Beijing GoBroad Hospital (the group's flagship research hospital in Changping). For hematological malignancies including CAR T-cell therapy, we route to Beijing GoBroad Boren Hospital or Lu Daopei Hospital; for pediatric hematology and thalassemia HSCT, to Nanfang-Chunfu Children's Institute. Our coordination service is free to the patient and covers preliminary case review, MDC submission, Chinese visa documentation, accommodation guidance in Shanghai and honest comparative assessment before any travel commitment.
| Hospital at a Glance | |
|---|---|
| Country | China |
| City | Shanghai (β VERIFY: specific district and street address with the International Consultation channel before publishing) |
| Established | β VERIFY: Specific Phase I opening date with the hospital; the hospital operates as part of GoBroad Healthcare Group (founded 2017) and is affiliated with China Pharmaceutical University |
| Hospital Type | Tertiary Cancer Research Hospital Β· Solid Tumour Specialty Centre of GoBroad Healthcare Group Β· Affiliated with China Pharmaceutical University |
| Accreditation | Registered drug clinical trial institution (Phase I-IV); active international academic engagement; β VERIFY: Specific JCI or EBMT institutional accreditation status of the Shanghai GoBroad campus before publishing |
| Beds | 406 beds in Phase I operations; approximately 700 additional beds under development in Phase II |
| Patient Activity | β VERIFY: Annual cancer patient volume with the hospital before publishing |
| Research Focus | Solid tumour clinical research, Phase I-IV drug clinical trials, multidisciplinary care (MDC) model for complex cancers, immune-combination therapy in hepatobiliary-pancreatic and biliary tract cancer, BRAF-mutant colorectal cancer, sarcoma, lung cancer and breast cancer programmes |
Why Patients Choose Shanghai GoBroad Cancer Hospital
Shanghai GoBroad Cancer Hospital combines a dedicated solid tumour specialty focus, leadership by internationally recognised oncologist Professor Qin Shukui, modern radiotherapy and imaging infrastructure including TomoTherapy and PET-CT, active Phase I-IV clinical trial access, and Shanghai's gateway-city advantages for international patients.
Cancer Specialties and Clinical Departments
Shanghai GoBroad Cancer Hospital is organised around five disease-focused solid tumour programmes, each with dedicated multidisciplinary tumour board review and access to active clinical trial protocols, supported by modern radiotherapy and imaging infrastructure.
Advanced Treatment Capabilities
Key Specialists at Shanghai GoBroad Cancer Hospital
Shanghai GoBroad Cancer Hospital's clinical leadership is anchored by Honorary President Professor Qin Shukui (秦ει΅), who also serves as Chief Consultant for Hepatobiliary-Pancreatic Tumours, Chief Physician, Professor and PhD supervisor. Professor Qin is one of China's most internationally recognised medical oncologists, with deep expertise in hepatocellular carcinoma, biliary tract cancer and pancreatic cancer. He is a leading figure in the Chinese Society of Clinical Oncology (CSCO) and has presented landmark Asian patient data from international studies including TOURMALINE for advanced biliary tract cancer first-line treatment. Additional senior faculty include Professor Li Jin (medical oncology, gastrointestinal cancer, clinical trials), Professor Lu Ming (hepatobiliary and gastrointestinal oncology, with concurrent nuclear medicine appointments in the wider GoBroad network), and disease-focused team leads across the hospital's five solid tumour programmes.
Patient care at Shanghai GoBroad Cancer Hospital is structured through a Multidisciplinary Care (MDC) model, considered the current international best practice for cancer treatment and care, bringing together surgical oncologists, medical oncologists, radiation oncologists, radiologists, pathologists, molecular biologists and supportive care teams for each complex case. International patients can request a multidisciplinary consultation through the hospital's dedicated International Consultation channel (η³θ―·ε½ι δΌθ―). Beyond the core full-time clinical team, the hospital draws on the wider GoBroad Healthcare Group's academic resources and research network across its seven research hospitals. Patients seeking specific physician consultations or focused multidisciplinary second opinions may request a review through the CancerFax coordination process before confirming travel, particularly for HPB cancer cases where consultation with Professor Qin or his team is one of the strongest reasons international patients choose Shanghai GoBroad.
Patients seeking specific physician consultations or second opinions may request a review through the CancerFax coordination process before confirming travel or admission.
Clinical Infrastructure and Treatment Technology
Shanghai GoBroad Cancer Hospital operates 406 beds in Phase I with approximately 700 additional beds under Phase II development, supported by Phase I clinical trial wards, a central laboratory, TomoTherapy linear accelerator, PET-CT and MRI imaging, and an active multidisciplinary care delivery model designed for complex solid tumour management.
- TomoTherapy linear accelerator for advanced image-guided helical IMRT radiotherapy
- PET-CT for staging, treatment response assessment and clinical trial eligibility screening
- MRI and 64-slice multi-layer CT for tumour characterisation, surgical planning and response monitoring
- Comprehensive surgical oncology across GI, lung, hepatobiliary-pancreatic, sarcoma and breast disease programmes
- Multidisciplinary tumour board pre-surgical review through the MDC model
- β VERIFY: specific robot-assisted surgical systems and interventional oncology capability with the hospital before publishing
- Registered drug clinical trial institution conducting Phase I through IV protocols
- Phase I clinical trial wards integrated with the central laboratory for early-phase oncology drug studies
- Immunotherapy combination protocols (immune-chemo) for hepatobiliary-pancreatic and biliary tract cancers; first in-hospital encorafenib dispensing for BRAF-mutant colorectal cancer in Shanghai
- Central laboratory supporting clinical trial protocols, molecular profiling and precision oncology workflow
- Molecular tumour board review for precision oncology treatment decisions and trial eligibility
- Hotel-style inpatient ward design, one-stop patient guidance service, psychological care and patient-community programmes including 'Light Corner' patient gatherings and festival patient-doctor solidarity events
International Patient Support at Shanghai GoBroad Cancer Hospital
Shanghai GoBroad Cancer Hospital operates a dedicated International Consultation channel (η³θ―·ε½ι δΌθ―) for patients travelling from outside China, supported by Shanghai's gateway-city advantages including two major international airports, expatriate-friendly infrastructure and broad Chinese visa convenience.
What to Prepare Before Traveling
- arrow_rightShare complete pathology reports, biopsy slides where requested for re-review, recent CT, PET-CT and MRI imaging, molecular profiling (including specific actionable mutations such as BRAF for colorectal cancer, EGFR/ALK/ROS1 for lung cancer, HER2 for gastric and breast cancers, KRAS for pancreatic cancer), prior treatment summaries and a current medication list (in English or Chinese) with CancerFax at least two weeks before any planned consultation, particularly important for clinical trial eligibility screening.
- arrow_rightApply for an appropriate Chinese visa (M for medical, L for tourist, or transit visa where eligible) at your nearest Chinese consulate. Shanghai GoBroad Cancer Hospital can issue an official invitation letter for the patient and accompanying family members; many nationalities also have access to 240-hour visa-free transit options for short stays in Shanghai. Plan travel via Shanghai Pudong International Airport (PVG) or Shanghai Hongqiao International Airport (SHA).
- arrow_rightAllow at least one to two weeks for an initial solid tumour consultation, multidisciplinary tumour board review and treatment planning, with longer stays for surgery (typically two to three weeks recovery), radiation oncology cycles (typically four to seven weeks for fractionated radiotherapy), or extended systemic therapy and clinical trial participation. Shanghai's expatriate-friendly infrastructure makes extended-stay planning more straightforward than many other Chinese cities.
Shanghai GoBroad Cancer Hospital can be contacted directly through shanghaigobroadhospital.com, which operates an English-language interface for international patients alongside the primary Chinese site. CancerFax coordinates all communication on the patient's behalf in Mandarin Chinese, manages translation, visa and travel arrangements, conducts comparative assessment with alternative Chinese and international cancer pathways, and remains the single point of contact through treatment and follow-up at no cost to the patient.
Patient Facilities and Accommodation at Shanghai GoBroad Cancer Hospital
Shanghai GoBroad Cancer Hospital offers a hotel-style inpatient ward environment with 406 beds in Phase I operations, designed for both clinical functionality and patient comfort, with one-stop patient guidance services, psychological care and patient-community programmes.
Family members accompanying international patients can stay at hotels and serviced apartments across Shanghai. As China's most internationally connected city, Shanghai offers extensive accommodation at all price points, multilingual hotel staff at international properties, and expatriate-friendly neighbourhoods including the former French Concession, Jing'an and Lujiazui. CancerFax can help plan budget-conscious extended-stay options for families travelling for longer treatment cycles such as radiotherapy or post-surgical recovery.
How to Reach Shanghai GoBroad Cancer Hospital
Shanghai GoBroad Cancer Hospital is located in Shanghai, China β the country's most internationally connected city, served by two major international airports and an extensive metro and high-speed rail network.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Shanghai GoBroad Cancer Hospital β Patient Questions Answered
CancerFax acts as your single Mandarin-speaking coordinator for the entire Shanghai GoBroad Cancer Hospital journey. You begin by sharing your complete oncology records β pathology, biopsy slides where re-review is requested, recent CT, PET-CT and MRI imaging, molecular profiling (including specific actionable mutations such as BRAF for colorectal cancer, EGFR/ALK/ROS1 for lung cancer, HER2 for gastric and breast cancers), prior treatment summaries β through our secure intake. Our clinical team reviews your case and identifies whether Shanghai GoBroad is the right clinical fit for your specific cancer, particularly for hepatobiliary-pancreatic, GI, lung, sarcoma or breast cancer cases where the hospital's disease-focused programmes are strongest. Where consultation with Professor Qin Shukui is clinically relevant β particularly for HPB cancers β we specifically request this.
Once your consultation is confirmed, CancerFax prepares your full pre-travel pack: the hospital's official cost estimate translated into English (shared with you without any CancerFax mark-up), Chinese visa documentation, accredited Chinese-English translation of your home-country reports, accommodation guidance across Shanghai including expatriate-friendly neighbourhoods, and travel logistics via Shanghai Pudong or Hongqiao International Airports. We remain your single point of contact through admission, treatment, in-patient stay and follow-up. Where useful, we will openly compare Shanghai GoBroad alongside alternative Chinese cancer centres including Cancer Hospital of the Chinese Academy of Medical Sciences, Sun Yat-sen University Cancer Center, Fudan University Shanghai Cancer Center and Beijing GoBroad Hospital before any travel commitment. There is no fee to the patient for any of this coordination.
Shanghai GoBroad Cancer Hospital is the solid tumour specialty centre within GoBroad Healthcare Group's seven-hospital research network across Beijing, Shanghai and Guangzhou. Each GoBroad hospital has a specific clinical focus: (i) Beijing GoBroad Hospital β the group's flagship research hospital in Changping ZhongGuanCun Life Science Park, opened in July 2023, with the broadest scope covering solid tumours, hematologic malignancies, neuroscience and Lu-177 radionuclide therapy; (ii) Beijing GoBroad Boren Hospital β the group's adult CAR T-cell therapy and hematology powerhouse with 4,000+ CAR-T cases and 30 different CAR-T targets; (iii) Shanghai GoBroad Cancer Hospital (this hospital) β the solid tumour specialty with 406 beds Phase I and ~700 beds Phase II under development, focused on GI, lung, HPB, sarcoma and breast cancers; (iv) Shanghai Zhaxin and Liquan Hospitals β adult hematology specialty within the Shanghai Ruijin Hospital Hematology Medical Consortium; and (v) Nanfang-Chunfu Children's Institute in Dongguan β the pediatric hematology and HSCT specialty centre with world-leading thalassemia transplant outcomes. CancerFax routes each case to the right GoBroad hospital based on diagnosis: solid tumours typically go to Shanghai GoBroad or Beijing GoBroad, hematology to Boren or Shanghai Zhaxin/Liquan, pediatric hematology to Nanfang-Chunfu.
Professor Qin Shukui (秦ει΅) is one of China's most internationally recognised medical oncologists, with particular focus on hepatocellular carcinoma (liver cancer), biliary tract cancer (cholangiocarcinoma and gallbladder cancer) and pancreatic cancer. He serves as Honorary President and Chief Consultant for Hepatobiliary-Pancreatic Tumours at Shanghai GoBroad Cancer Hospital. Professor Qin has been a leading voice in the Chinese Society of Clinical Oncology (CSCO), including recent leadership at the 9th CSCO Jinling Tumour Annual Conference on advances in liver cancer immunotherapy, and presented Asian patient data from the TOURMALINE study supporting flexible first-line immune combination chemotherapy in advanced biliary tract cancer. For families with HCC, intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer or pancreatic cancer β particularly cases where immune-combination protocols, locoregional therapy (TACE, ablation) or systemic targeted therapy decisions are complex β consultation with Professor Qin or his team is one of the strongest clinical reasons to consider Shanghai GoBroad. CancerFax can specifically request this consultation as part of your case submission.
Yes. Shanghai GoBroad Cancer Hospital actively accepts foreign-language oncology records and provides written opinions before any travel commitment, particularly for solid tumour cases where the multidisciplinary care decision can largely be made from records alone β pathology, imaging, molecular profiling and prior treatment history. The process involves submitting your records through the International Consultation channel (η³θ―·ε½ι δΌθ―), which CancerFax facilitates on your behalf with accredited Chinese-English translation. The MDC team reviews the case and provides a written opinion covering proposed treatment plan, eligibility for any ongoing Phase I-IV clinical trial protocols relevant to your diagnosis, estimated cost and timeline. CancerFax can also arrange parallel remote second opinions from Cancer Hospital of the Chinese Academy of Medical Sciences, Sun Yat-sen University Cancer Center, Fudan University Shanghai Cancer Center or other internationally recognised cancer centres so the family can make a well-informed decision before committing to international travel.
As a Chinese tertiary cancer research hospital, Shanghai GoBroad Cancer Hospital offers solid tumour treatment at substantially lower cost than equivalent care in the United States, the United Kingdom, Singapore or the Gulf, often by a factor of three to five for comparable surgery, radiotherapy and supportive care. Costs are broadly comparable with other major Chinese private and research-oriented cancer hospitals, with some variation: pricing is typically higher than government-sector cancer hospitals such as Fudan University Shanghai Cancer Center or Cancer Hospital of the Chinese Academy of Medical Sciences (Beijing), but typically more accessible for international patients given the dedicated International Consultation channel, hotel-style ward design and English-language interface. For patients enrolling on active Phase I-IV clinical trial protocols, the investigational drug component is typically supplied at no cost as part of trial participation, though baseline care costs remain the patient's responsibility. CancerFax shares the hospital's official cost estimates with you at no extra charge and without any CancerFax mark-up, and we are happy to compare them openly with both Chinese and international cancer treatment alternatives before any decision is made. We always recommend asking for a 'complication contingency' estimate alongside the base treatment cost, particularly for surgical and HPB cancer cases where post-treatment supportive care can be substantial.
Send Your Medical Reports to Shanghai GoBroad Cancer Hospital via CancerFax
CancerFax reviews your records, assesses whether Shanghai GoBroad's solid tumour programmes are the right fit for your cancer, requests consultation with Professor Qin Shukui or other named specialists where clinically appropriate, compares Shanghai GoBroad alongside alternative Chinese cancer pathways, and coordinates your consultation or remote second opinion at no cost, with no obligation, and with full medical confidentiality throughout.